Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

BACKGROUND: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG)....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lee, Eudocia Q., Reardon, David A., Schiff, David, Drappatz, Jan, Muzikansky, Alona, Grimm, Sean A., Norden, Andrew D., Nayak, Lakshmi, Beroukhim, Rameen, Rinne, Mikael L., Chi, Andrew S., Batchelor, Tracy T., Hempfling, Kelly, McCluskey, Christine, Smith, Katrina H., Gaffey, Sarah C., Wrigley, Brendan, Ligon, Keith L., Raizer, Jeffrey J., Wen, Patrick Y.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483124/
https://ncbi.nlm.nih.gov/pubmed/25572329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou350
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars